Adverum Biotechnologies, INC 10-Q quarterly reports

Adverum Biotechnologies announced a definitive merger agreement with Eli Lilly and Company, alongside reporting significant Q3 operating losses and ongoing clinical trial progress for its lead gene therapy candidate, Ixo-vec.

Adverum Biotechnologies reports increased losses and substantial doubt about its ability to continue as a going concern, despite advancing its lead gene therapy candidate Ixo-vec into Phase 3 trials and securing a $10 million private placement.

Adverum Biotechnologies announces its Q1 2025 financial results, highlighting progress in its Ixo-vec clinical trials while acknowledging substantial doubt about its ability to continue as a going concern without additional funding.

Adverum Biotechnologies reports a net loss of $27.1 million for the third quarter of 2024, while progressing its lead product candidate, Ixo-vec, towards Phase 3 clinical trials.

Adverum Biotechnologies reports a net loss of $18.5 million for the second quarter of 2024, while highlighting progress in its Ixo-vec clinical program and financial stability.

Adverum Biotechnologies reports a net loss of $24.8 million for the first quarter of 2024, while highlighting progress in its clinical programs and a strengthened cash position.